ARKG - ARK Genomic Revolution Multi-Sector ETF
| Previous Close | 31.85 |
| Open | 31.89 |
| Bid | 31.71 x 800 |
| Ask | 33.00 x 900 |
| Day's Range | 31.73 - 32.15 |
| 52 Week Range | 21.98 - 35.54 |
| Volume | 95,733 |
| Avg. Volume | 130,615 |
| Net Assets | 428.14M |
| NAV | 31.88 |
| PE Ratio (TTM) | N/A |
| Yield | 0.00% |
| YTD Return | 32.61% |
| Beta (3Y Monthly) | 2.06 |
| Expense Ratio (net) | 0.75% |
| Inception Date | 2014-10-30 |
- Zacks
ETFs Poised to Benefit from Gene Editing Revolution
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
- Zacks
ETFs to Gain From the Booming Genomics Market
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.
- Zacks
Top-Performing Biotech ETFs YTD
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
- Zacks
5 U.S. ETFs Seeing Fireworks Ahead of July Fourth
These ETFs focus exclusively on U.S. equities and deserve the attention of investors seeking a domestic tilt to their portfolio ahead of the Jul 4 holiday.
- Zacks
5 Sector ETFs That Beat the Market in the First Half
With just a trading session left to end the first half, the Dow Jones is up about 13.7% while the S&P 500 and Nasdaq have gained 16.7% and 20.1%, respectively.
- Zacks
Why These Innovative Biotech ETFs Soaring
Strong M&A activity has sent shares of many small, innovative biotech companies surging
- ETF Database
4 ETFs to Help Investors Access Innovative Disruptors
New disruptive technologies are changing the way we interact with the world, providing growth opportunities for exchange traded fund investors whom are looking to diversify into these quickly developing segments.
- ETF Trends
4 ARK ETFs to Help Investors Access Innovative Disruptors
New disruptive technologies are changing the way we interact with the world, providing growth opportunities for exchange traded fund investors whom are looking to diversify into these quickly developing ...
- Zacks
S&P 500 Hits New High: 10 Top-Performing ETFs YTD
Braving global growth concerns, the bulls are back with the S&P 500 surging to its first record close since April.
- Zacks
Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.
- Zacks
ETF Winners & Losers As China Retaliates
The renewed trade spat has led to just a few winners but a number of losers from various corners of the investing space.
- ETF Trends
3 Biotech Sector ETFs Bucked the Risk-Off Trend
While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats to raise Chinese tariffs, biotechnology stocks and sector-related exchange traded ...
- Zacks
Forget Earnings Recession: Tap Revenue Growth With These ETFs
First-quarter earnings growth is likely to be negative this year, but revenues will grow. So, play revenue growth with these sector ETFs.
- Zacks
Biotechnology Market on a Tear: 5 ETFs in Spotlight
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
- Zacks
Global X Launches GNOM ETF to Tap Booming Genomics Space
Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.
- Zacks
Best Performing ETFs of the First Quarter
Major indexes posted their best quarterly performance since the financial crisis; here are some ETFs that soared during the quarter
- ETF Trends
5 ETFs That Were on Fire in the First Quarter
With the books closing on the first quarter of 2019, it’s been a strong start for U.S. equities–the Dow Jones Industrial is up 12.56 percent through Monday’s close, the S&P 500 is up 14.37 percent and ...
- Motley Fool
These 3 ETFs Have Crushed It in 2019
Find out how one of these exchange-traded funds took investors higher than any other.
- Zacks
ETFs That Topped & Flopped in Q1
We have highlighted both the best and worst performing ETFs of Q1 from different zones or industries.
- Zacks
4 Market-Beating Sector ETFs of the First Quarter
We have highlighted four sector ETFs that have been the quarter's star performers and could also be winners next quarter if the current trends continue.
- Zacks
4 Best-Performing Sector ETFs of March
A few sector ETFs have easily outperformed the market and are trading in the green this month.
- ETF Trends
A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements
A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (NasdaqGS: EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug ...
- ETF Database
Biotech ETF Strengthens on Optimism Over CRISPR Advancements
A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug candidate and its expansion into other novel CRISPR developments.
